SCHEMBL4373559

SCHEMBL4373559

CC(C)CN(CC(O)C(N)Cc1ccccc1)S(=O)(=O)c1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPPL2A Q8TCT8 3/20 0.76
PSEN1 P49768 1/20 0.53
PSEN2 P49810 1/20 0.53
APH1B Q8WW43 1/20 0.53
NCSTN Q92542 1/20 0.53
APH1A Q96BI3 1/20 0.53
PSENEN Q9NZ42 1/20 0.53
RORC P51449 4/20 0.50
TAS2R14 Q9NYV8 1/20 0.50
MLNR O43193 1/20 0.50
ABCB11 O95342 1/20 0.50
LMNA P02545 1/20 0.50
CTSD P07339 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP3A5 P20815 1/20 0.50
CNR1 P21554 1/20 0.50
TBXAS1 P24557 1/20 0.50
ADRA1A P35348 1/20 0.50
ABCB1 P08183 1/20 0.47
KCNE1 P15382 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4911140 1.00 SPPL2A (0.76) SPPL2APSEN1PSEN2APH1BNCSTN
SCHEMBL1051190 0.94 SPPL2A (0.74) SPPL2APSEN1PSEN2APH1BNCSTN
SCHEMBL10031792 0.94 SPPL2A (0.74) SPPL2APSEN1PSEN2APH1BNCSTN
SCHEMBL608142 0.94 SPPL2A (0.74) SPPL2APSEN1PSEN2APH1BNCSTN
SCHEMBL9605440 0.94 SPPL2A (0.74) SPPL2APSEN1PSEN2APH1BNCSTN
SCHEMBL23129692 0.94 SPPL2A (0.74) SPPL2APSEN1PSEN2APH1BNCSTN
SCHEMBL1054059 0.93 SPPL2A (0.73) SPPL2APSEN1PSEN2APH1BNCSTN
Hydrochloric Acid SCHEMBL14637729 0.93 SPPL2A (0.73) SPPL2APSEN1PSEN2APH1BNCSTN
Hydrochloric Acid SCHEMBL14636197 0.93 SPPL2A (0.73) SPPL2APSEN1PSEN2APH1BNCSTN
SCHEMBL16727690 0.93 SPPL2A (0.73) SPPL2APSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2877474-B1 A PROCESS FOR PREPARATION OF DARUNAVIR LAURUS LABS LTD (IN) 2020-11-04 EP claimed
EP-2877474-A2 A PROCESS FOR PREPARATION OF DARUNAVIR Laurus Labs Private Limited (IN) 2015-06-03 EP claimed
WO-2014016660-A2 A PROCESS FOR PREPARATION OF DARUNAVIR LAURUS LABS PRIVATE LIMITED (IN) 2014-01-30 WO claimed
EP-3795572-B1 DARUNAVIR PROPIONATE SOLVATE LAURUS LABS LTD (IN) 2023-11-15 EP disclosed
EP-3795572-A1 DARUNAVIR PROPIONATE SOLVATE Laurus Labs Limited (IN) 2021-03-24 EP disclosed
EP-2877474-B1 A PROCESS FOR PREPARATION OF DARUNAVIR LAURUS LABS LTD (IN) 2020-11-04 EP disclosed
EP-2877474-B1 A PROCESS FOR PREPARATION OF DARUNAVIR LAURUS LABS LTD (IN) 2020-11-04 EP disclosed
EP-2477992-B1 PROCESSES FOR THE PREPARATION OF DARUNAVIR AND THE AMORPHOUS FORM THEREOF MYLAN LABORATORIES LTD (IN) 2016-12-14 EP disclosed
US-20160355525-A1 PROCESS FOR PREPARATION OF DARUNAVIR LAURUS LABS LIMITED (IN) 2016-12-08 US disclosed
EP-2877474-A2 A PROCESS FOR PREPARATION OF DARUNAVIR Laurus Labs Private Limited (IN) 2015-06-03 EP disclosed
US-8703980-B2 Process for the preparation of darunavir TIANISH LABORATORIES PRIVATE LIMITED (IN) 2014-04-22 US disclosed
WO-2014016660-A2 A PROCESS FOR PREPARATION OF DARUNAVIR LAURUS LABS PRIVATE LIMITED (IN) 2014-01-30 WO disclosed
WO-2013114382-A1 CRYSTALLINE DARUNAVIR MYLAN LABORATORIES LTD (IN) 2013-08-08 WO disclosed
WO-2013011485-A1 PROCESS FOR THE PREPARATION OF SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2013-01-24 WO disclosed
CN-1898248-B Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate TIBOTEC PHARM LTD 2011-08-17 CN disclosed
EP-1725566-B1 PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE TIBOTEC PHARM LTD (IE) 2009-06-17 EP disclosed
CN-1898248-A Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate TIBOTEC PHARM LTD (IE) 2007-01-17 CN disclosed
EP-1725566-A1 PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE Tibotec Pharmaceuticals Ltd. (IE) 2006-11-29 EP disclosed
WO-2005063770-A1 PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160355525-A1 PROCESS FOR PREPARATION OF DARUNAVIR SAMHD1, CYP3A5, DARS1 SPPL2A 4665/4885PSEN1 3308/4885PSEN2 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.